JP2008529497A5 - - Google Patents

Download PDF

Info

Publication number: JP2008529497A5
Authority: JP; Japan
Prior art keywords: antibody; isolated antibody; epha2; antigen; chain variable
Prior art date: 2006-02-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2007554287A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008529497A (ja

JP5342145B2 (ja

Filing date

2006-02-06

Publication date

2009-04-02

2006-02-06 Application filed filed Critical

2006-02-06 Priority claimed from PCT/US2006/004057 external-priority patent/WO2006084226A2/en

2008-08-07 Publication of JP2008529497A publication Critical patent/JP2008529497A/ja

2009-04-02 Publication of JP2008529497A5 publication Critical patent/JP2008529497A5/ja

2013-11-13 Application granted granted Critical

2013-11-13 Publication of JP5342145B2 publication Critical patent/JP5342145B2/ja

2026-02-06 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

210000004027 cell Anatomy 0.000 claims 34
102000051096 EphA2 Receptor Human genes 0.000 claims 26
108010055196 EphA2 Receptor Proteins 0.000 claims 26
239000012634 fragment Substances 0.000 claims 26
239000000427 antigen Substances 0.000 claims 25
108091007433 antigens Proteins 0.000 claims 25
102000036639 antigens Human genes 0.000 claims 25
206010028980 Neoplasm Diseases 0.000 claims 9
201000011510 cancer Diseases 0.000 claims 9
101150042817 NFS1 gene Proteins 0.000 claims 8
101100126298 Rickettsia conorii (strain ATCC VR-613 / Malish 7) iscS gene Proteins 0.000 claims 8
101150114492 SPL1 gene Proteins 0.000 claims 8
150000007523 nucleic acids Chemical group 0.000 claims 8
239000003814 drug Substances 0.000 claims 7
108020004707 nucleic acids Proteins 0.000 claims 7
102000039446 nucleic acids Human genes 0.000 claims 7
229940124597 therapeutic agent Drugs 0.000 claims 7
108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
239000008194 pharmaceutical composition Substances 0.000 claims 3
238000000338 in vitro Methods 0.000 claims 2
238000001727 in vivo Methods 0.000 claims 2
238000000034 method Methods 0.000 claims 2
239000000203 mixture Substances 0.000 claims 2
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims 2
210000004881 tumor cell Anatomy 0.000 claims 2
230000004614 tumor growth Effects 0.000 claims 2
108060003951 Immunoglobulin Proteins 0.000 claims 1
108091028043 Nucleic acid sequence Proteins 0.000 claims 1
239000013604 expression vector Substances 0.000 claims 1
210000004408 hybridoma Anatomy 0.000 claims 1
102000018358 immunoglobulin Human genes 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000003550 marker Substances 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
239000013598 vector Substances 0.000 claims 1

JP2007554287A 2005-02-04 2006-02-06 ＥｐｈＡ２に結合する抗体およびその使用方法 Expired - Fee Related JP5342145B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65004705P	2005-02-04	2005-02-04
US60/650,047		2005-02-04
PCT/US2006/004057 WO2006084226A2 (en)	2005-02-04	2006-02-06	Antibodies that bind to epha2 and methods of use thereof

Publications (3)

Publication Number	Publication Date
JP2008529497A JP2008529497A (ja)	2008-08-07
JP2008529497A5 true JP2008529497A5 (2)	2009-04-02
JP5342145B2 JP5342145B2 (ja)	2013-11-13

Family

ID=36778009

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2007554287A Expired - Fee Related JP5342145B2 (ja)	2005-02-04	2006-02-06	ＥｐｈＡ２に結合する抗体およびその使用方法

Country Status (16)

Country	Link
US (3)	US7569672B2 (2)
EP (1)	EP1846450B1 (2)
JP (1)	JP5342145B2 (2)
KR (1)	KR101363252B1 (2)
CN (2)	CN104059150B (2)
AT (1)	ATE551367T1 (2)
AU (1)	AU2006210460B2 (2)
BR (1)	BRPI0607450A2 (2)
CA (1)	CA2597198C (2)
CR (1)	CR9332A (2)
IL (1)	IL184803A (2)
MX (1)	MX2007009403A (2)
NO (1)	NO20074474L (2)
RU (1)	RU2007133108A (2)
WO (1)	WO2006084226A2 (2)
ZA (1)	ZA200707275B (2)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6927203B1 (en) *	1999-08-17	2005-08-09	Purdue Research Foundation	Treatment of metastatic disease
US7192698B1 (en) *	1999-08-17	2007-03-20	Purdue Research Foundation	EphA2 as a diagnostic target for metastatic cancer
KR101363252B1 (ko) *	2005-02-04	2014-02-13	레이븐 바이오테크놀로지스, 인코퍼레이티드	Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
AU2006287416A1 (en) *	2005-09-07	2007-03-15	Medimmune, Llc	Toxin conjugated Eph receptor antibodies
EA020324B1 (ru) *	2006-07-18	2014-10-30	Санофи-Авентис	АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
EP2109668A4 (en)	2007-01-22	2011-10-05	Macrogenics West Inc	HUMAN CANCER STEM CELLS
KR20100056438A (ko) *	2007-06-18	2010-05-27	메디뮨 엘엘씨	ＥｐｈＡ2 및 ＥｒｂＢ2를 발현하는 세포의 상승적 치료 방법
SI2199390T1 (sl)	2007-08-30	2017-02-28	Daiichi Sankyo Company, Limited	Proti-epha2 protitelo
WO2009085805A2 (en) *	2007-12-21	2009-07-09	Siemens Heathcare Diagnostics Inc.	Circulating epha2 receptor
JP5785490B2 (ja)	2008-04-02	2015-09-30	マクロジェニクス，インコーポレーテッド	Ｂｃｒ複合体特異的抗体およびその使用方法
JP5117917B2 (ja)	2008-04-21	2013-01-16	デクセリアルズ株式会社	保護素子及びその製造方法
EP2346525A4 (en)	2008-10-02	2012-05-09	Celtaxsys Inc	METHODS OF MODULATION OF NEGATIVE CHIMOTAXIA OF IMMUNE CELLS
ES2733067T3 (es)	2008-12-19	2019-11-27	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
UY32914A (es)	2009-10-02	2011-04-29	Sanofi Aventis	Anticuerpos que se usan específicamente al receptor epha2
US20120288481A1 (en) *	2009-11-09	2012-11-15	The Brigham And Women's Hospital, Inc.	Treatment of heart disease
US20120321595A1 (en)	2009-11-09	2012-12-20	The Brigham And Women's Hospital, Inc.	Treatment of heart disease
PH12018501083A1 (en)	2010-03-04	2019-02-18	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2012012759A2 (en) *	2010-07-22	2012-01-26	The Regents Of The University Of California	Anti-tumor antigen antibodies and methods of use
MX339622B (es)	2010-08-02	2016-06-02	Macrogenics Inc	Diacuerpos covalentes y sus usos.
EA201391753A1 (ru)	2011-05-21	2014-08-29	Макродженикс, Инк.	Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
CN103857700A (zh)	2011-08-26	2014-06-11	梅里麦克制药股份有限公司	串联fc双特异性抗体
EP2764082B1 (en) *	2011-10-04	2018-05-23	Expression Pathology, Inc.	Srm/mrm assay for the ephrin type-a receptor 2 protein
JP5875054B2 (ja) *	2013-02-13	2016-03-02	国立大学法人東京大学	がんの検査方法及び検査用キット
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CA2902505A1 (en)	2013-03-06	2014-09-12	Merrimack Pharmaceuticals, Inc.	Anti-c-met tandem fc bispecific antibodies
SG10201913680PA (en)	2014-05-29	2020-03-30	Macrogenics Inc	Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
KR101636882B1 (ko) *	2015-06-25	2016-07-06	전남대학교 산학협력단	인간 피브로넥틴 도메인 Ⅲ 기본 골격의 신규 인간 ＥｐｈＡ2 특이적 결합 단백질 및 그의 용도
AU2016298227B9 (en)	2015-07-30	2019-10-31	Macrogenics, Inc.	PD-1-binding molecules and methods of use thereof
JP6955507B2 (ja)	2015-12-14	2021-10-27	マクロジェニクス，インコーポレーテッド	Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
US11534466B2 (en)	2016-03-09	2022-12-27	Aal Scientifics, Inc.	Pancreatic stem cells and uses thereof
CA3020864A1 (en)	2016-04-15	2017-10-19	Macrogenics, Inc.	Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
JPWO2018135653A1 (ja) *	2017-01-23	2020-01-09	学校法人東洋大学	抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
JP7132232B2 (ja)	2017-02-24	2022-09-06	マクロジェニクス，インコーポレーテッド	Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
JP2021505637A (ja)	2017-12-12	2021-02-18	マクロジェニクス，インコーポレーテッド	二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
SG11202007572VA (en)	2018-02-15	2020-09-29	Macrogenics Inc	Variant cd3-binding domains and their use in combination therapies for the treatment of disease
JP7326764B2 (ja) *	2018-03-09	2023-08-16	東ソー株式会社	腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法
JP7745556B2 (ja)	2020-02-21	2025-09-29	マクロジェニクス，インコーポレーテッド	Ｃｄ１３７結合分子及びその使用
US20230233698A1 (en) *	2020-06-12	2023-07-27	Bicycletx Limited	Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
WO2022250431A1 (ko)	2021-05-25	2022-12-01	주식회사 박셀바이오	모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포
KR20230140746A (ko) *	2022-03-30	2023-10-10	연세대학교 산학협력단	암전이의 검출용 신규 바이오마커

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US6054561A (en) *	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5552391A (en) *	1990-01-16	1996-09-03	La Jolla Pharmaceutical Company	Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) *	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
GB9115364D0 (en) *	1991-07-16	1991-08-28	Wellcome Found	Antibody
CA2078539C (en) *	1991-09-18	2005-08-02	Kenya Shitara	Process for producing humanized chimera antibody
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5714350A (en) *	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) *	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5824303A (en) *	1992-11-13	1998-10-20	Amgen Inc.	Eck receptor ligands
US6210671B1 (en) *	1992-12-01	2001-04-03	Protein Design Labs, Inc.	Humanized antibodies reactive with L-selectin
US6180377B1 (en) *	1993-06-16	2001-01-30	Celltech Therapeutics Limited	Humanized antibodies
US5532159A (en) *	1994-04-01	1996-07-02	The Ohio State University	Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
AU776675B2 (en)	1998-12-22	2004-09-16	Macrogenics West, Inc.	Compositions and methods for generating monoclonal antibodies representative of a specific cell type
DE60045075D1 (de) *	1999-08-17	2010-11-18	Purdue Research Foundation	Anti-epha2 antikörper als krebsdiagnostikum
AU6784400A (en)	1999-08-17	2001-03-13	Glaxo Group Limited	Treatment of metastatic disease
US6927203B1 (en) *	1999-08-17	2005-08-09	Purdue Research Foundation	Treatment of metastatic disease
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
US6406840B1 (en)	1999-12-17	2002-06-18	Biomosaic Systems, Inc.	Cell arrays and the uses thereof
US6541225B1 (en) *	2000-01-26	2003-04-01	Raven Biotechnologies, Inc.	Methods and compositions for generating human monoclonal antibodies
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
FR2838742B1 (fr) *	2002-04-23	2004-07-09	Inst Nat Sante Rech Med	Epitopes t de l'antigene epha2
ATE525398T1 (de) *	2002-05-10	2011-10-15	Medimmune Inc	Epha2 monoklonale antikörper und deren anwendungsverfahren
EP1575509B1 (en)	2002-05-10	2011-10-26	Purdue Research Foundation	Epha2 agonistic monoclonal antibodies and methods of use thereof
KR101363252B1 (ko) *	2005-02-04	2014-02-13	레이븐 바이오테크놀로지스, 인코퍼레이티드	Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법

2006
- 2006-02-06 KR KR1020077019628A patent/KR101363252B1/ko not_active Expired - Fee Related
- 2006-02-06 BR BRPI0607450-2A patent/BRPI0607450A2/pt not_active Application Discontinuation
- 2006-02-06 AT AT06734397T patent/ATE551367T1/de active
- 2006-02-06 AU AU2006210460A patent/AU2006210460B2/en not_active Ceased
- 2006-02-06 MX MX2007009403A patent/MX2007009403A/es active IP Right Grant
- 2006-02-06 CA CA2597198A patent/CA2597198C/en not_active Expired - Fee Related
- 2006-02-06 CN CN201410213409.1A patent/CN104059150B/zh not_active Expired - Fee Related
- 2006-02-06 CN CN200680011089.5A patent/CN101155830B/zh not_active Expired - Fee Related
- 2006-02-06 RU RU2007133108/13A patent/RU2007133108A/ru not_active Application Discontinuation
- 2006-02-06 JP JP2007554287A patent/JP5342145B2/ja not_active Expired - Fee Related
- 2006-02-06 EP EP06734397A patent/EP1846450B1/en not_active Expired - Lifetime
- 2006-02-06 US US11/349,327 patent/US7569672B2/en not_active Expired - Fee Related
- 2006-02-06 WO PCT/US2006/004057 patent/WO2006084226A2/en not_active Ceased
- 2006-02-06 ZA ZA200707275A patent/ZA200707275B/xx unknown
2007
- 2007-07-24 IL IL184803A patent/IL184803A/en not_active IP Right Cessation
- 2007-08-22 CR CR9332A patent/CR9332A/es not_active Application Discontinuation
- 2007-09-03 NO NO20074474A patent/NO20074474L/no not_active Application Discontinuation
2009
- 2009-06-30 US US12/495,218 patent/US7776328B2/en not_active Expired - Fee Related
- 2009-11-30 US US12/627,335 patent/US8183357B2/en not_active Expired - Fee Related

Publication	Publication Date	Title
RU2007133108A (ru)	2009-03-10	АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
JP2021184721A5 (2)	2022-07-12
JP2019146572A5 (2)	2019-12-19
JP2021526022A5 (2)	2022-05-31
JP2019107018A5 (2)	2019-09-19
JP2024059609A5 (2)	2024-07-23
JP2022191301A5 (2)	2023-05-29
JP2014509835A5 (2)	2015-02-12
JP2020019787A5 (2)	2020-03-26
JP2013543498A5 (2)	2014-12-11
JP2017522861A5 (2)	2019-04-25
JP2022533538A5 (2)	2023-05-16
JP2020522280A5 (2)	2021-07-26
JP2006507013A5 (2)	2008-07-03
JP2010533498A5 (2)	2011-07-21
JP2020534830A5 (2)	2021-10-28
JP2017529838A5 (2)	2018-10-11
JP2020522281A5 (2)	2021-07-26
JP2009297037A5 (2)	2011-01-20
JP2010526028A5 (2)	2011-04-07
JP2024531409A5 (2)	2025-08-26
NZ597067A (en)	2012-08-31	Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2008529489A5 (2)	2009-04-02
JP2012525854A5 (2)	2015-05-28
JP2011207882A5 (2)	2012-06-21